Profound Medical to Participate in Lake Street’s BIG9 Conference

Profound Medical ( (TSE:PRN) ) has shared an update.

Profound Medical announced its participation in the Lake Street Capital Markets ‘BIG9’ Conference on September 11, 2025, in New York City, where management will engage in one-on-one investor meetings. This participation underscores the company’s ongoing efforts to strengthen its market presence and engage with potential investors, which could have implications for its growth and industry positioning.

The most recent analyst rating on (TSE:PRN) stock is a Buy with a C$11.00 price target. To see the full list of analyst forecasts on Profound Medical stock, see the TSE:PRN Stock Forecast page.

Spark’s Take on TSE:PRN Stock

According to Spark, TipRanks’ AI Analyst, TSE:PRN is a Neutral.

Profound Medical’s stock score reflects the company’s strong revenue growth and strategic potential, balanced by operational inefficiencies and financial challenges. Technical indicators suggest caution due to bearish trends, while valuation remains a concern with negative earnings. Positive earnings call sentiment and future growth prospects are encouraging, yet immediate operational improvements are necessary for sustained success.

To see Spark’s full report on TSE:PRN stock, click here.

More about Profound Medical

Profound Medical Corp. is a commercial-stage medical device company specializing in customizable, incision-free therapies for the ablation of diseased tissue. The company is known for its TULSA-PRO® system, which offers a non-invasive treatment for prostate diseases, and Sonalleve®, a platform for treating uterine fibroids and bone metastases. Profound Medical’s technologies are approved by various health authorities, including the FDA, Health Canada, and the China National Medical Products Administration.

Average Trading Volume: 8,110

Technical Sentiment Signal: Sell

Current Market Cap: C$186.9M

Learn more about PRN stock on TipRanks’ Stock Analysis page.